Al­ler­gan vet Doug In­gram takes the helm of a storm-tossed Sarep­ta

Ex-Al­ler­gan Pres­i­dent Doug In­gram has been tapped to take charge at Sarep­ta Ther­a­peu­tics $SRPT, the lat­est in a se­ries of CEOs who will now lead the charge sell­ing the con­tro­ver­sial Duchenne mus­cu­lar dy­s­tro­phy drug Ex­ondys 51.

In­gram last popped up on the biotech radar last fall af­ter he sold Chase Phar­ma­ceu­ti­cals to Brent Saun­ders, who had merged Ac­tavis in Al­ler­gan and kept the biotech name for the larg­er op­er­a­tion. At Chase, In­gram had steered the biotech through a small but suc­cess­ful Phase II Alzheimer’s study, then gained $125 mil­lion up­front in a bil­lion-dol­lar deal to sell the com­pa­ny to Al­ler­gan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER